MRPL39

Across TCGA pan-cancer cohorts, MRPL39 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRPL39 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRPL39 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL39 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MRPL39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.358	0.794	<.001	61	view →
LUAD	DFS	Tertile	III,IV	0.746	0.281	.030	4	view →
PDAC	DFS	Tertile	IV	0.777	0.217	.024	3	view →
GBM	OS	Quartile	All	0.679	0.436	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRPL39–CCRCC (DFS)

Open the CCRCC breakdown →